Chemical and Biological Defense Program - EMD

Abstract

This program element (PE) resources System Development & Demonstration across the Understand, Protect, Mitigate, and Enabling Investments portfolios. The Chemical Biological Defense Programs (CBDP) investments provide an integrated, layered capability to enable Countering Weapons of Mass Destruction (CWMD) missions ranging from combat operations to Department of Defense (DoD) support to domestic incident prevention and response. The projects in this PE support the development, build, and test of products to verify that all operational and derived requirements have been met and to support production or deployment decisions. The activities include mature system development, integration, and demonstration to support Milestone C decisions, and conducting operational tests and evaluation of production representative articles. FY25 funding accelerates characterization and situational awareness of emerging biothreats and accelerates delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines. Individual Projects include: - Understand (UN5): Provides the Joint Force the ability to detect and identify hazards from traditional and emerging chemical and biological threats to improve the timeliness and confidence of information for decision-makers. Supports freedom of maneuver and informs commanders' decisions by predicting, locating, identifying, analyzing, and warning of chemical and biological (CB) hazards. - Protect (PT5): Provides the Joint Force the ability to prevent the effects of exposure to chemical and biological hazards. Protects personnel against chemical, biological, and radiological (CBR) liquid, vapor, and aerosol hazards through next-generation prototypes of masks, filters, and ensembles to reduce physiological, psychological, and logistical burdens to the warfighter. Medical countermeasure efforts conducted during this phase include the development of a large-scale manufacturing process and validation of that process, nonclinical studies, demonstration of manufacturing consistency, and expanded clinical human safety studies. Focuses on platform-based approaches to accelerate the development of prophylactic medical countermeasures that rapidly and durably protect against Biological Warfare Agents (BWAs), toxins, non-traditional and emerging chemical threats with minimal doses. The results of these efforts will be used to submit a Biologics License Application (BLA) to the U.S. Food & Drug Administration (FDA) for product licensure. - Mitigate (MT5): Preserves combat power by mitigating exposure to CB hazards and restoring combat readiness of critical personnel and platforms. Enables Joint Force lethality by providing capabilities for Warfighters to rapidly respond to and mitigate the adverse effects of CB hazards. Fields mitigation capabilities against engineered biological agents, opioids and other Pharmaceutical-Based Agents, and Fourth Generation Agents (FGAs). - Enabling Investments (EN5): Provides fundamental knowledge and technology demonstrations as key portfolio enablers integral to responding to emerging threats. Dedicated funding for this Project supports National and Departmental incident response and preparedness regarding CB threats. Middle Tier Acquisition programs: The total cost of the Uniform Integrated Protective Ensemble Family of Systems Gloves (UIPE FOS GLOVES) Middle Tier of Acquisition effort is $58.924 Million, including RDT&E (Project PT5) and procurement of prototype units (CBDP BLIN Protection & Hazard Mitigation). The UIPE FOS GLOVES is fully funded across the Future Years Defense Program. The projects in this PE support the engineering and manufacturing development phase of the Department of Defense (DoD) acquisition system and are, therefore, correctly placed in Budget Activity 5.

Open PDF

Document Details

Document Type
R2 Budgetary Justification
Publication Date
Oct 01, 2025
Source ID
0604384BP_5_0400_PB_2025
Change Summary Explanation
Funding: FY 2023 (-$6.209 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts. FY 2023 (-$0.628 Million): CBDP funding transferred to Under Secretary of Defense (Acquisition & Sustainment) high priority efforts. FY 2025 (-$43.747 Million) The overall decrease of (-$43.747 Million) primarily includes a decrease to the Antiviral Oral Therapeutic (AVO TX) program Budget Activity 5 (BA5) by transitioning funding to BA4 to support AVO TX FDA engagements needed for a successful Milestone B decision and transition of medical countermeasure development activities to the Rapid Access to Products in Development (RAPID) program (-$25.825 Million), a System Development & Demonstration (SDD) adjustment to support DoD high priority efforts (-$18.696 Million), and a inflation rate adjustment increase (+$0.774 Million). Schedule: N/A Technical: N/A
Service Agency Name
Chemical and Biological Defense Program

Tags

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.
  • Defense Acquisition Program Management
  • Military Science and Technology Research and Modernization.

Technology Areas

  • Biotechnology

Related Documents